Scholarlink

<p>The landscape of gastro-oesophageal adenocarcinoma (GEA) management has undergone substantial transformation over the past decade owing to shifts in epidemiology, evolving treatment paradigms and the integration of new therapeutic strategies. The global burden of GEA continues to rise, with differing patterns observed in Asia compared with Western countries. Important insights gleaned from recent high-profile clinical trials — both successful and negative — have considerably reshaped perioperative treatment strategies, redefining the roles of chemotherapy, radiotherapy, immune checkpoint inhibitors and targeted therapies. Although still investigational, organ-preserving approaches and circulating tumour DNA (ctDNA)-based patient stratification are shaping the direction of future GEA management. By consolidating these developments, this Review aims to provide clinicians and researchers with a comprehensive and structured guide to the state-of-the-art perioperative management of GEA, emphasizing the underlying biology, clinical implications and future directions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizons

  • 期刊论文

  • 发表日期：

    2026年5月15日

查看全文
  • Hongcheng Zhu,
  • Florian Lordick,
  • Yelena Y. Janjigian,
  • Sun Young Rha,
  • Magnus Nilsson,
  • Kohei Shitara,
  • Richard Owen,
  • Zhen Zhang,
  • Elizabeth C. Smyth

摘要

The landscape of gastro-oesophageal adenocarcinoma (GEA) management has undergone substantial transformation over the past decade owing to shifts in epidemiology, evolving treatment paradigms and the integration of new therapeutic strategies. The global burden of GEA continues to rise, with differing patterns observed in Asia compared with Western countries. Important insights gleaned from recent high-profile clinical trials — both successful and negative — have considerably reshaped perioperative treatment strategies, redefining the roles of chemotherapy, radiotherapy, immune checkpoint inhibitors and targeted therapies. Although still investigational, organ-preserving approaches and circulating tumour DNA (ctDNA)-based patient stratification are shaping the direction of future GEA management. By consolidating these developments, this Review aims to provide clinicians and researchers with a comprehensive and structured guide to the state-of-the-art perioperative management of GEA, emphasizing the underlying biology, clinical implications and future directions.